GNT Induction Treatment in Locally Advanced NPC - Trial NCT06026878
Access comprehensive clinical trial information for NCT06026878 through Pure Global AI's free database. This Phase 3 trial is sponsored by Air Force Military Medical University, China and is currently Recruiting. The study focuses on Nasopharyngeal Carcinoma. Target enrollment is 228 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Air Force Military Medical University, China
Timeline & Enrollment
Phase 3
Sep 01, 2023
Sep 30, 2027
Primary Outcome
overall response rate
Summary
The goal of this clinical trial is to compare overall response rate between gemcitabine,
 nimotuzumab and toripalimab as induction treatment and gemcitabine combined with cisplatine
 in paitents with locally advanced nasopharyngeal carcinoma. It aims to answer whether
 gemcitabine, nimotuzumab and toripalimab as induction treatment show non-inferiority compared
 to GP induction chemotherapy. Participants will be randomly divided into two induction
 treatment groups.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06026878
Non-Device Trial